Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 2, 2005, Pages 641-647

  Kraft, Birgit ^a   Kress, Hans G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; CANNABINOID 2 RECEPTOR; METHANANDAMIDE; AMIDE; ARACHIDONIC ACID DERIVATIVE; CYCLOHEXANOL DERIVATIVE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL ISOLATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; MOLECULAR WEIGHT; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; RESPIRATORY BURST; BLOOD; DRUG EFFECT; IN VITRO STUDY; METABOLISM; STIMULATION;

ARACHIDONIC ACIDS; CANNABINOIDS; CYCLOHEXANOLS; CYCLOOXYGENASE INHIBITORS; HUMANS; LIPOXYGENASE INHIBITORS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; POLYUNSATURATED ALKAMIDES; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB2; RESPIRATORY BURST; STIMULATION, CHEMICAL;

EID: 27144518080     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.084269     Document Type: Article

References (43)

1. Audette CA and Burstein SH (1990) Inhibition of leukocyte adhesion by the in vivo and in vitro administration of cannabinoids. Life Sci 47:753-759.
2. Baldwin CG, Tashkin DP, Buckley DM, Park AN, Dubinett SM, and Roth MD (1997) Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Resp Crit Care Med 156:1606-1613.
3. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, and Casellas P (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214:173-180.
4. Burstein SH, Hull K, Hunter SA, and Letham V (1988) Cannabinoids and pain responses: a possible role for prostaglandins. FASEB J 2:3022-3026.
5. Conroy MC, Randinitis EJ, and Turner JL (1991) Pharmacology, pharmacokinetics and therapeutic use of meclofenamate sodium. Clin J Pain 7 (Suppl 1):44-48.
6. Daniels I, Lindsay MA, Keany CIC, Burden RP, Fletcher J, and Haynes AP (1998) Role of arachidonic acid and its metabolites in the priming of NADPH oxidase in human polymorphonuclear leukocytes by peritoneal dialysis effluent. Clin Diagn Lab Immunol 5:683-689.
7. Derocq JM, Segui M, Marchand J, Le Fur G, and Casellas P (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369:177-182.
8. Deusch E, Kraft B, Nahlik G, Weigl L, Hohenegger M, and Kress HG (2003) No evidence for direct modulatory effects of delta 9-tetrahydrocannabinol on human polymorphonuclear leukocytes. J Neuroimmunol 141:99-103.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash DC) 258:1946-1949.
10. Diaz S, Specter S, Vanderhoek JY, and Coffey RG (1994) The effect of delta-9-tetrahydrocannabinol on arachidonic acid metabolism in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 268:1289-1296.
11. Di Marzo V, De Petrocellis L, Bisogno T, and Melck D (1999) Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids 34:319-325.
12. 9-tetrahydrocannabinol on human neutrophil function. Drug Abuse Immunomodul Immunodefic 288:57-61.
13. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, and Campbell WB (1998) Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54:180-188.
14. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
15. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, and Hipkin RW (2000) Endocannabinoid 2-arachidonylglycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57:1045-1050.
16. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
17. Hunter SA and Burstein SH (1997) Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci 60:1563-1573.
18. Klein TW, Kawakami Y, Newton C, and Friedman H (1991) Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health 32:465-477.
19. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, and Friedman H (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496.
20. Klein TW, Newton C, and Specter S (1998) Marijuana, immunity and infection. J Neuroimmunol 83:102-115.
21. Klein TW, Newton CA, Widen R, and Friedman H (1985) The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on Tlymphocyte and B-lymphocyte mitogen responses. J Immunopharmacol 7:451-466.
22. Kraft B, Wintersberger W, and Kress HG (2004) Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. Life Sci 75:969-977.
23. Liu J, Liu Z, Chuai S, and Shen X (2003) Phospholipase C and phosphatidylinositol 3-kinase signalling are involved in the exogenous arachidonic acid-stimulated respiratory burst in human neutrophils. J Leukoc Biol 74:428-437.
24. Lopez-Cepero M, Friedman M, Klein TW, and Friedman H (1986) Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro. J Leukoc Biol 39:679-686.
25. Martin BR, Mechoulam R, and Razdan RK (1999) Discovery and characterization of endogenous cannabinoids. Life Sci 65:637-644.
26. Massi P, Fuzio D, Vigano D, Sacerdote P, and Parolaro D (2000) Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)- tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 387:343-347.
27. Parij N, Nagy AM, Fondu P, and Neve J (1998) Effects of non-steroidal antiinflammatory drugs on the luminol and lucigenin amplified chemiluminescence of human neutrophils. Eur J Pharmacol 352:299-305.
28. Perez-Reyes M, Burstein SH, White WR, McDonald SA, and Hicks RE (1991) Antagonism of marihuana effects by indomethacin in humans. Life Sci 48:507-515.
29. Pestonjamasp VK and Burstein SH (1998) Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochem Biophys Acta 1394:249-260.
30. Ramos CL, Pou S, and Rosen GM (1994) Effect of antiinflammatory drugs on myeloperoxidase-dependent hydroxyl radical generation by human neutrophils. Biochem Pharmacol 49:1079-1084.
31. Reichmann M, Nen W, and Hokin LE (1987) Effects of delta 9-tetrahydrocannabinol on prostaglandin formation in brain. Mol Pharmacol 32:686-690.
32. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra M, et al. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
33. Rothe G, Oser A, and Valet G (1998) Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes. Naturwissenschaften 75:354-355.
34. Rouzer CA, Ghebreselasie K, and Marnett LJ (2002) Chem stability of 2-arachidonylglycerol under biological conditions. Chem Phys Lipids 119:69-82.
35. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, and Turner H (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170:4953-4962.
36. Sarafian TA, Magallanes JA, Shau H, Tashkin DP, and Roth MD (1999) Oxidative stress produced by marijuana smoke: an adverse effect enhanced by cannabinoids. Am J Resp Cell Mol Biol 20:1286-1293.
37. Schatz AR, Lee M, Condie RB, Pulaski JT, and Kaminski NE (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142:278-287.
38. Shivachar AC, Martin BR, and Ellis EF (1996) Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methyl-1H-pyrazole-3-carboximide hydrochloride]. Biochem Pharmacol 51:669-676.
39. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, and Metters KM (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352-361.
40. Streefkerk JO, Pfaffendorf M, and van Zwieten PA (2003) Endothelium-dependent, vasopressin-induced contractions in rabbit renal arteries. J Cardiovasc Pharmacol 42:703-709.
41. Sugiura T and Waku K (2000) 2-Arachidonylglycerol and the cannabinoid receptors. Chem Phys Lipids 108:89-106.
42. Wright CD, Kuipers PJ, Kobylarz-Singer D, Devall LR, Klinkefus BA, and Weishaar RE (1990) Differential inhibition of human neutrophil functions: role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem Pharmacol 40:699-707.
43. 9-THC enhances the secretion of interleukin 1 from endotoxin stimulated macrophages. J Pharmacol Exp Ther 270:1334-1339.